EnglishУкраїнська
  • Main
  • Useful links
  • Information for Contributors
  • About
  • Editorial board

  • Article
    Petryk I. A., Hodakivskyi O. A., Prokopenko S. V.

    THE EVALUATION OF THE CORTISOL TITERS DYNAMIC IN THE BLOOD OF RATS CORONARY SINUS UNDER THE SIMULATED PITUITRIN-IZADRYNE MYOCARDIAL INFARCTION


    About the author: Petryk I. A., Hodakivskyi O. A., Prokopenko S. V.
    Heading EXPERIMENTAL MEDICINE
    Type of article Scentific article
    Annotation The acute (7 days) and recovery (21 days) periods of pituitrin-izadryne infarction (MI) in rats are followed by the increase of cortisone titers in the blood of the coronary sinus by 6.13 and 3.58 times respectively, which points both at the distress progression in conditions of the acute coronary syndrome and the steroid cardiotoxicity development. The preventive-therapeutic intraperitoneal administration of Corvitin (10 mg/kg intraperitoneal) to rats prevents the development of the above-mentioned pathology attested by the probable de-escalation of cortisol titers in the acute and recovery periods of myocardial infarction compared to the control pathology group at an average by 5.79 and 3.82 times, respectively. The prophylactic administration before ischemia simulating and subsequent therapeutic administration during acute and recovery periods of MI 3,2'-spiro-pyrrolo-2-oxyndole derivate (compound R-86) at a conditionally effective dose of 10 mg/kg intragastrically completely prevented the escalation of the investigational hormone level confirmed by the absence of reliable differences in the cortisol level of intact group of animals. The modulating effect of 3,2'-spiro-pyrrolo-2-oxindole derivative (compound R-86) and Corvitin on the steroid cardiotoxicity developing may be one of mechanisms of its cardioprotective action.
    Tags pituitrin-izadryne myocardial infarction, 3,2'-spiro-pirrolo-2-oxindole derivate (compound R-86), Corvitin, Сortisol
    Bibliography
    • Bagauri O. V. Ckrining antigipoksichnoyi aktivnosti v ryadu novih pohidnih 3,2’-spiro-pirolo-2-oksindolu / O. V. Bagauri, R. G. Redkin, O. A. Hodakivskiy // Visnik farmatsiyi. – 2013. – No.2(74). – S. 63–65.
    • Braverman L. B. Porivnyalna otsinka vplivu pohidnogo 3,2'-spiro-pirrolo-2-oksindolu (spoluka R-86) ta tsitikolinu na dinamiku neyrodestruktivnih zmin pri modelnomu Intratserebralnomu krovovilivi / L. B. Braverman // Visnik morfologiyi. – 2014. – No. 2, T.19– S. 247-251.
    • Kutasevich Ya. F. Sluchay kortikosteroidnoy kardiomiopatii u bolnogo psoriazom, dlitelno poluchavshego lechenie glyukokortikosteroidami / Ya. F. Kutasevich, I. A. Oleynik // DermatologIya ta venerologIya. –2012.No.1 (55).  –S. 99–102.
    • Petrik I. A. Moduliruyuschee deystvie proizvodnogo 3,2'-spiro-pirrolo-2-oksindola na formirovanie steroidnoy neyrotoksichnosti, kardiotserebralnoy disfunktsii i techenie neyroapoptoza v usloviyah eksperimentalnogo ishemicheskogo insulta / I. A. Petrik, O. V. Hodakovskaya, S. Yu. Shtryigol[i dr.] // Vrach-aspirant. – Voronezh, -2014. – No. 6(67). – S. 44–53.
    • Petrik I. O. Monitoring kardioprotektornih efektiv pohidinogo 3,2'-spiro-pirrolo-2-oksindolu spoluki R-86 pri modelnIy kardialniy ishemiyi za riznih rezhimiv vvedennya / I. O. Petrik // Visnik Vinnitskogo natsionalnogo medichnogo universitetu. – 2014. – T. 18, No. 2. – S. 441–444.
    • Hodakivskiy O. A. Patogenetichne obgruntuvannya dotsilnosti vikoristannya novih pohidnih adamantanu pri eksperimentalniy terapiyi gostroyi ishemiyi golovnogo mozku ta miokarda: avtoref. dis. na zdobuttya nauk. stupenya doktora med. nauk / O. A. Hodakivskiy. – Odesa., -2014. – 32 s.
    • Hodakivska O. V. Tserebroprotektorna aktivnist novih pohIdnih 3,2'-spiro-pirolo-2-oksindolu v umovah ishemichnogo insultu (eksperimentalne doslidzhennya): avtoref. dis. na zdobuttya nauk. stupenya kandidata farm. nauk / O. V. Hodakivska // – Harkiv., -2015. – 20 s.
    • Hodakovskaya O. V. Neyrohimicheskie mehanizmyi tserebroprotektornogo deystviya proizvodnogo spiro [indol-3,1'-pirrol[3,4-s]pirrola] / O. V. Hodakovskaya, D. V. Evdokimov, S. Yu. Shtryigol [i dr.] // Obzoryi po klinicheskoy farmakologii i lekarstvennoy terapii. – Sankt-Peterburg, -2015. – T.14, No.1. – S.56-61.
    • Belda X. Acute stress induced sensitization of the pituitary–adrenal response to heterotypic stressors: Independence of glucocorticoid release and activation of CRH1 receptors / X. Belda, N. Daviu, R. Nadal [et al.] // Hormones and Behavior. – 2012. – Vol. – 62. – Р. 515–524.
    • Lipson V. V. Development of 11-βHSD1 inhibitors for the treatment of metabolic syndrome / V. V. Lipson, L. L. Zamigajlo, O. N. Petrova // Ukrainica Bioorganica Acta. – 2011. – Vol. 2. – P. 3–13.
    • Mac.Lullich M. J. 11-hydroxysteroid dehydrogenase type 1, brain atrophy and cognitive decline / M. J. Mac.Lullich, K. J. Ferguson, M. L. Reid // Neurobiology of Aging. – 2012. – Vol. 33. – Р 207–207.
    • Ying F. Emodin, a natural product, selectively inhibits 11βhydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in dietinduced obese mice /F. Ying,H. Suling,D. Wei [et al.] // British J. Pharmacol. – 2010–Vol. 161. – P. 113–126.
    Publication of the article «World of Medicine and Biology» №3(57), 2016 year, 130-134 pages, index UDK 616.831-006.4-009:548.756